Region:
All editionsMethodologyUpdated · May 2026
Vendors/particle-peptidesData verified: 2026-05
VID-PARTICLE-P · SK · est. 2014

Particle Peptides

Slovakia · EN · SK
Editor's pickEU warehouseGDPRAffiliate 15% / 10%

The gold standard for EU research peptides. Only vendor offering 7-parameter independent blind multi-lab testing including peptide content via CLND detector, bioburden, and heavy metals — all to European Pharmacopoeia standards.

Composite score
9.2/10
▲ rank #1 of 12
Testing
10.0
Purity
9.0
EU-fit
9.0
Value
8.0
Trust
9.0
History · incidents · milestones

Vendor timeline.

  • Jun 01, 2024
    Awarded Editor's Choice

    First in this region to receive the Editor's Choice rating.

  • Jan 01, 2014
    Particle Peptides founded

    Incorporated in Slovakia.

Certificate of Analysis · specimen batch

The full COA. Nothing redacted.

Below is an actual representative batch sent for independent blind multi-lab testing. Every parameter referenced to public pharmacopoeia monographs.

Certificate of Analysis · BPC-157
BATCH · PP-BPC-2401-A3 · LOT LX241014
PDF · on request
Manufactured
2024-10-14
Expires
2026-10-14
Size
5 mg · lyophilised
Lab
Janoshik
MethodParameterSpecificationResultStatus
HPLCPurity≥ 98.0%99.3%pass
LC-MSIdentity (MW)1419.6 ± 0.5 Da1419.56 Dapass
FTIRStructuralMatch referenceMatchpass
CLNDPeptide content≥ 95.0%97.1%pass
LALEndotoxin< 5 EU/mg< 0.1 EU/mgpass
TAMC/TYMCBioburden< 100 CFU/g< 10 CFU/gpass
ICP-MSHeavy metalsPh.Eur. 2.4.20Below LOQpass
Verdict

What we like · what we don't.

Pros

  • 7-parameter independent COA — most comprehensive in EU segment
  • GMP-approved: inspected by FDA, EMA, TGA, NMPA, MFDA
  • ISO 9001 + ISO 13485 certified
  • European Pharmacopoeia compliant
  • Free worldwide shipping from EU
  • Only EU vendor with documented affiliate program
  • 4.9/5 Trustpilot from 308 verified reviews

×Cons

  • Higher price point vs. competitors
  • Strict returns — defective items only
  • Affiliate program for entrepreneurs only
  • Limited language support (EN + SK only)
  • 2–3 business day processing delays (Q1 2026)